GSK’s Daprodustat Approved by FDA
FDA announced the approval of GSK’s daprodustat as Jesduvroq for the treatment of CKD anemia in dialysis-dependent (DD) patients. The approval comes after multiple CRLs for Fibrogen/AZ’s roxadustat and Akebia/Otsuka’s vadadustat. The Jesduvroq label has not yet been observed. Below, FENIX provides brief thoughts on the Jesduvroq approval.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.